drugset / Trial / NCT01492465
Single Ascending Dose Trial in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether AMG 876 is safe and well tolerated in subjects with type 2 diabetes.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-07
- Completion
- 2012-10
Outcome
Outcome not reported
Stopped: “Decision by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efruxifermin | Protein / enzyme biologic | — | Subcutaneous |